Christante Dara, Pommier SuEllen, Garreau Jennifer, Muller Patrick, LaFleur Brett, Pommier Rodney
Division of Surgical Oncology, Department of Surgery, Portland, OR, USA.
Am J Surg. 2008 Oct;196(4):505-11. doi: 10.1016/j.amjsurg.2008.06.023.
We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research.
Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured.
Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100% survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone.
HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar.
我们之前报道过，使用激素替代疗法（HRT）的乳腺癌患者肿瘤分期显著较低，生存率高于从未使用者。我们提供一项随访时间更长、HRT使用数据及体外研究的更新报告。
我们将292例绝经后乳腺癌患者的数据库进行更新，纳入HRT类型、使用时长及疾病状态。测定雌激素（E）和/或甲羟孕酮（MPA）对乳腺癌细胞生长的体外作用。
任何使用时长的E使用者及联合使用HRT者的肿瘤预后因素均更佳，生存率更高。使用超过10年与淋巴结阴性疾病、乳腺钼靶检测到的肿瘤及100%生存率相关。E仅支持最低限度的增殖；MPA诱导细胞死亡；E+MPA的结果与单独使用E相似。
HRT使用者，无论HRT的类型或使用时长如何，生存率持续较高。体外研究结果支持了E和E+MPA使用者结局相似的临床发现。
